BBI PPP:投资欧洲37亿欧元重振生物基经济

  • 欧洲,投资,生物基经济,生物基产业
  • 中国科学报

欧洲生物基产业公私伙伴(BBI PPP)日前宣布,将对生物基产业(BBI)运用一项新的“欧洲联合企业”形式,并在2014~2024年投资37亿欧元,为生物基和“欧洲制造”产品创造更具竞争力的市场,吸引更多投资。

据悉,在BBI PPP 预计投资的37亿欧元中,9.75亿欧元将来自欧盟委员会,27亿来自生物基产业联盟(BIC)。而“联合企业”负责专门的实体管理和经营,由欧盟委员会和公司代表构成董事会,共同就资金分配进行决策。BBI PPP的目标是利用欧洲尚未开发的生物质和废物,如进料来制造能源消耗品以及更绿色的日常消耗品。其中最核心的是利用先进的生物炼制及创新技术将可再生资源转变成可持续的生物基化学制品、材料和能源。

在欧洲从依靠化石能源与进口向可持续经济增长的转型中,BBI PPP起到了推进作用。该计划有望创造数以万计的工作机会,而且80%的工作机会将出现在农村地区,有望振兴工业,提升农民收入,将温室效应气体排放减少一半以上。


主管研究、创新与科技的欧盟委员Máire Geoghegan-Quinn表示:“生物经济的巨大潜力吸引着全世界的投资,通过这种合作形式,我们可以运用创新技术,将尚未利用的可再生资源与废物转化成日常生活所需的绿色制品,如食物、饲料、化学制品、能源等,这些都能全部来源于欧洲并由欧洲制造。”

作为该欧洲生物基产业公私伙伴计划的一员,全球工业酶制剂和微生物制剂的主导企业诺维信的CEO Peder Holk Nielsen认为:“BBI PPP是前所未见的公私合作组织,因为它致力于将生物基技术带入市场,这是我们在欧洲获得可持续增长的机会。”

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.